Citi analyst Samantha Semenkow initiates coverage on $BioAge Labs (BIOA.US)$ with a buy rating, and sets the target price at $45.
According to TipRanks data, the analyst has a success rate of 38.8% and a total average return of -8.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs, a clinical-stage biotech centered on developing treatments for metabolic diseases, is advancing its lead asset, azelaprag, an oral small molecule that stimulates the apelin receptor and is currently in development for obesity. The company's shares are considered to have a favorable risk/reward profile leading up to the STRIDES readout. The product's oral formulation and ease of manufacturing, coupled with strong preclinical data, suggest it could have a promising clinical profile for treating obesity.
Initial findings indicate that BioAge Labs' azelaprag shows promise, potentially enhancing weight loss when used alongside GLP-1s, and also contributing to better body composition and higher quality of weight loss. Early data suggest that azelaprag not only facilitates weight reduction but also has a positive effect on muscle.
BioAge Labs, a clinical stage biotechnology firm concentrating on metabolic diseases, is recognized for its lead drug Azelaprag, which stands out due to its unique mechanism that mimics exercise, targeting obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析师Samantha Semenkow首予$BioAge Labs (BIOA.US)$买入评级，目标价45美元。
根据TipRanks数据显示，该分析师近一年总胜率为38.8%，总平均回报率为-8.2%。
此外，综合报道，$BioAge Labs (BIOA.US)$近期主要分析师观点如下：
BioAge实验室是一家临床阶段的生物技术公司，专注于开发治疗代谢性疾病的治疗方法，正在推进其主力资产艾瑟帕格（azelaprag），一种口服小分子药物，可刺激阿佩林受体，目前正在开发用于肥胖症。公司的股票被认为具有有利的风险/回报特征，导致STRIDES数据公布前的期待。产品的口服配方和制造便利性，再加上强大的临床前数据，表明它在治疗肥胖症方面可能具有有望的临床特点。
初步发现表明BioAge实验室的艾瑟帕格显示出潜力，可能在与GLP-1s联合使用时增强减重效果，并有助于改善体质和提高减重的质量。早期数据表明，艾瑟帕格不仅有助于减轻体重，还对肌肉有积极影响。
BioAge实验室是一家临床阶段的生物技术公司，专注于代谢性疾病，以其主力药物艾瑟帕格而闻名，该药物因模拟运动的独特机制而脱颖而出，瞄准肥胖症。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
